Concordance between the updated Elecsys cerebrospinal fluid immunoassays and amyloid positron emission tomography for Alzheimer’s disease assessment: findings from the Apollo studyHenrik Schinkeon March 11, 2025 at 10:00 am
Clin Chem Lab Med. 2025 Mar 13. doi: 10.1515/cclm-2024-1476. Online ahead of print. ABSTRACT OBJECTIVES: The Apollo study was designed to support the clinical performance verification of the adjusted cutoffs of the Elecsys® β-Amyloid(1-42) (Aβ42) cerebrospinal fluid (CSF) II, β-Amyloid(1-40) (Aβ40) CSF, Phospho-Tau (181P) (pTau) CSF and Total-Tau (tTau) CSF immunoassays (Roche Diagnostics International Ltd) … Read more
